Aurobindo Pharma shares up 4% after Q2 PAT rises 26% YoY

Consolidated revenue from operations grew by 15.8 percent year-on-year to Rs 6,483.3 crore with the US formulation business showing a 12.5 percent growth YoY at Rs 3,189.8 crore in Q2.

Read Full Story on MoneyControl

Enter your email address:


We will be happy to hear your thoughts

      Leave a reply

      IndiaClicking - Buzzing News & Stocks